GlaxoSmithKline News and Research

RSS

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals for the development of an active vaccination programme against Alzheimer's disease.

1 Mar 2011

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical programmes have been completed successfully. The second programme was related to alternative vaccine candidates generated by AFFiRiS´ AFFITOME® technology, including candidate AD03. Based on the promising preliminary results of this programme, GSK exercised its option for the alternative vaccine candidates which triggered a EUR 2.5 million payment to AFFiRiS. An additional EUR 1 million payment became due simultaneously for the successful completion of tests of alternative vaccine formulations.

28 Feb 2011

FDA approves GSK's PROMACTA to treat rare blood disorder

GlaxoSmithKline today announced that the United States Food and Drug Administration granted full approval for PROMACTA, an oral tablet that can raise platelet counts in patients with the rare blood disorder chronic immune thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

27 Feb 2011

Experts at ICAO warn about risk of cardiometabolic consequences in overweight individuals

Experts meeting at the 2nd International Congress on Abdominal Obesity today issued a warning that millions of individuals around the globe are at risk from the cardiometabolic consequences of being overweight. Worryingly, the experts suggest that these people are not being identified by their doctors.

25 Feb 2011

Report finds neglected diseases research funding up in 2009, funding for related non-profits down

"A rise in global funding for research into neglected diseases needs to be matched by a continued focus on delivering practical new ways to curb sickness in the developing world," according to the third annual report by the Global Funding of Innovation for Neglected Diseases released on Wednesday, Reuters reports.

18 Feb 2011

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

Flu vaccine update

This new vaccine which could become available in the United States in the next few years, is made by growing the influenza virus in cultures of animal cells rather than in the chicken eggs that have been used for more than five decades. This shortens the process by six months. Using animal cells, which are grown in enclosed steel tanks, also reduces the risk of bacterial contamination, which has led to shortages of seasonal vaccines in some years. The study was reported in The Lancet this Tuesday.

16 Feb 2011

Also in global health news: Gates Foundation global health head to step down; drug, medical supply shortages in Gaza; food security in N. Korea

Tachi Yamada, president of the global health program at the Bill & Melinda Gates Foundation, on Monday announced he would step down in June after five years serving in the position, the Associated Press/Seattle Post-Intelligencer reports.

16 Feb 2011

GAVI chair calls for greater reductions in vaccine prices for developing countries

On Monday, the same day the GAVI Alliance helped oversee the roll out of a routine pneumococcal vaccine in Kenya, GAVI chairman Dagfinn Hoybraten highlighted the need for greater reductions in vaccine prices in developing countries during an interview with Reuters, the news service reports. The piece examines the funding mechanism in place to finance the pneumococcal vaccines, known as Advance Market Commitment (AMC), as well as the budget shortfall facing the group (Kelland, 2/14).

16 Feb 2011

Pneumococcal vaccine officially rolled out in Kenya

"Kenya on Monday became the first African country to introduce a routine vaccine against pneumococcal disease, which claims the lives of more than half a million children under five each year," Deutsche Presse Agentur/The Hindu reports. The GAVI Alliance, which is supporting the vaccine's roll out, "is aiming to introduce the vaccine to 19 developing countries - including Nicaragua, Guyana, Yemen and Sierra Leone - within a year and hopes to reach more than 40 nations by 2015, depending on funding."

15 Feb 2011

HIV infection in mothers reduces disease resistance in babies: Study

New research suggests that babies whose mothers have HIV, but are not HIV-infected themselves, are born with lower levels of specific proteins in their blood called antibodies, which fight infection, compared with babies not exposed to HIV.

13 Feb 2011

Idenix announces updates on HCV and HIV clinical development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs.

10 Feb 2011

Benson Group listed on 'Europe's 500' top growth companies

Europe's 500, the association of top European growth entrepreneurs met at the European Parliament in Brussels on February 3rd for the European Growth Summit 2011. An integral part of the event, the "Europe's 500" awards ceremony honoured the top-growth-companies in Europe, and released a list of the 200 fastest-growing, job-creating businesses.

10 Feb 2011

ASC launches ACT NOW to offer support, education about asthma and respiratory allergies

In response to increasing public enquiries for information on respiratory allergies, the Asthma Society of Canada announced today the launch of Allergies Count Too, NOW a program that will fill the gap in allergy education and provide critical information to Canadians.

9 Feb 2011

The Lancet journal publishes BENLYSTA BLISS-52 study against SLE

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.

7 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

Economist Conferences to holding 17th annual The Pharma Summit 2011 in London

Economist Conferences is holding its 17th annual The Pharma Summit 2011 in London on Thursday February 10 2011. The theme this year is 'Reinventing Pharma for a new generation' and will bring together over 150 senior executives from across the Pharma sector, including some of the industry's most influential names.

3 Feb 2011

Swine flu shots linked to narcolepsy: Investigation continues

The vaccine used against swine flu has been linked to a disorder called narcolepsy among those aged four to 19. Narcolepsy involves people falling asleep without warning or sleeping excessively in the daytime. A preliminary study also “observed [an] increase in incidence of narcolepsy” among those given the vaccine.

2 Feb 2011

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

GlaxoSmithKline is being sued this week by a French father-of-two, alleging the British pharmaceutical firm’s drug – Reqip (Ropirnirole) to treat Parkinson’s disease turned him into a gay sex and gambling addict. Parkinson’s disease is a seriously and progressively debilitating disease that leads to tremors, slowing of movements and ultimately total immobility.

1 Feb 2011

Quest Diagnostics to repurchase 15.4M shares from GSK affiliate

Quest Diagnostics Incorporated today announced that it had agreed to repurchase at a negotiated price 15.4 million shares of its common stock from its largest shareholder, an affiliate of GlaxoSmithKline plc (GSK). Subsequent to the transaction, GSK will no longer hold any shares of common stock of Quest Diagnostics.

From Quest Diagnostics 1 Feb 2011

GlaxoSmithKline News and Research

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

FDA approves GSK's PROMACTA to treat rare blood disorder

Experts at ICAO warn about risk of cardiometabolic consequences in overweight individuals

Report finds neglected diseases research funding up in 2009, funding for related non-profits down

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Flu vaccine update

Also in global health news: Gates Foundation global health head to step down; drug, medical supply shortages in Gaza; food security in N. Korea

GAVI chair calls for greater reductions in vaccine prices for developing countries

Pneumococcal vaccine officially rolled out in Kenya

HIV infection in mothers reduces disease resistance in babies: Study

Idenix announces updates on HCV and HIV clinical development programs

Benson Group listed on 'Europe's 500' top growth companies

ASC launches ACT NOW to offer support, education about asthma and respiratory allergies

The Lancet journal publishes BENLYSTA BLISS-52 study against SLE

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Economist Conferences to holding 17th annual The Pharma Summit 2011 in London

Swine flu shots linked to narcolepsy: Investigation continues

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

Quest Diagnostics to repurchase 15.4M shares from GSK affiliate

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News